Actively Recruiting
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Led by Sinocelltech Ltd. · Updated on 2026-01-29
292
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
CONDITIONS
Official Title
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed multiple myeloma (IMWG criteria) not eligible for transplant
- Evidence of measurable disease
- Adequate organ function and blood counts
- Use contraception during the study and for 5 months after last dose; no donation of reproductive cells during this period
You will not qualify if you...
- Other blood-related cancers
- Confirmed or suspected central nervous system involvement
- Uncontrolled infection
- Significant health conditions affecting safety or study assessments (heart, lungs, endocrine, immune system, liver, digestive system, cancer)
- Major surgery or serious injury within 4 weeks before starting study drug, or planned elective surgery during study
- Received live or weakened vaccine within 30 days before first dose
- Currently breastfeeding (female participants)
- Mental disorders, poor compliance, or other conditions making participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Chaoyang Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here